Compare Aterian Inc (ATER) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs GSK plc — how do they compare? Aterian Inc trades at $1.25 (market cap $12.98M), while GSK plc trades at $51.63 (market cap $101.55B). The key difference: GSK plc is far larger — about 7823.6× Aterian Inc's market cap, and GSK plc pays a 3.5% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| ATER | GSK | |
|---|---|---|
Market Cap | $12.98M | $101.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $61.18 |
52-Week Low | $0.54 | $36.20 |
Enterprise Value | $13.56M | $122.16B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $1.19, up 3.48% with a bullish technical signal despite negative profitability. Recent earnings beats and a pending asset sale that could return $0.85-$1.14 per share provide near-term catalysts. However, the company shows declining revenue from $221M in 2022 to $69M in 2025, with negative net income margins and cash flow challenges.
The outlook hinges on shareholder approval of the brand portfolio sale, offering potential shareholder returns near current price levels. Investment opportunity exists in the asset sale catalyst, but risks include ongoing operational losses, declining revenue, and negative cash flow. Analyst sentiment is evenly split between Buy and Hold recommendations.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
